Atresia Pulmonal

01Pathophysiology

Pulmonary atresia is a cyanotic congenital heart defect characterized by complete absence of anatomic continuity between the right ventricle and the pulmonary artery. The pulmonary valve fails to develop, creating a membranous or muscular plate where the valve should be. This means the right ventricle cannot eject blood into the pulmonary circulation through normal pathways.

Because the right ventricle has no forward outlet, systemic venous blood returning to the right heart has no direct route to reach the lungs. The infant's survival depends entirely on alternative pathways for pulmonary blood flow. The two principal shunts that sustain life are the patent ductus arteriosus (PDA), which allows aortic blood to flow retrograde into the pulmonary arteries, and the patent foramen ovale (PFO) or an atrial septal defect (ASD), which permits right-to-left shunting at the atrial level so that blood can reach the left heart and then be redirected to the lungs via the PDA. This is why pulmonary atresia is classified as a duct-dependent lesion: once the ductus arteriosus undergoes physiologic closure in the first hours to days of life, pulmonary blood flow drops precipitously and the infant develops profound, life-threatening cyanosis.

The severity of presentation depends heavily on the subtype. In PA with intact ventricular septum (PA/IVS), the right ventricle is often hypoplastic because it has been pressure-loaded against a blind outflow tract throughout fetal life. The high RV pressure may force the development of sinusoidal communications between the RV cavity and the coronary arteries, creating an RV-dependent coronary circulation. This is a critical concept: if the coronary blood supply depends on the high-pressure RV, surgical decompression of the RV can cause coronary steal and myocardial ischemia. In contrast, PA with VSD functions similarly to severe tetralogy of Fallot. The VSD allows right-to-left shunting at the ventricular level, and the pulmonary blood supply often comes through major aortopulmonary collateral arteries (MAPCAs) rather than through a well-formed ductus alone.

The net result in both subtypes is obligatory mixing of oxygenated and deoxygenated blood, producing systemic arterial desaturation. The degree of cyanosis correlates directly with how much blood ultimately reaches the pulmonary vascular bed.

02Classification and Clinical Manifestation

An important clinical distinction: neonates with PA/IVS tend to present earlier and more critically because the RV contributes almost nothing to forward flow, and ductal closure is catastrophic. Those with PA/VSD may have a more variable timeline depending on the extent of collateral vessels, though they remain critically ill.

03Diagnostic Workup

The diagnostic sequence in practice begins with pulse oximetry in the newborn nursery. A cyanotic neonate who does not improve with supplemental oxygen should undergo a hyperoxia test: this is the bedside test that separates cardiac from pulmonary causes of cyanosis. If $Pa{O}_{2}PaO\_2$ fails to rise above 100 mmHg on 100% oxygen, the cause is presumed cardiac until proven otherwise.

Echocardiography is then the single most important diagnostic study. It is both the best initial test and the most accurate noninvasive test. On echo, you will see a blind-ending right ventricular outflow tract with no valve leaflet excursion, and the examiner can assess the size of the RV cavity, the tricuspid valve annulus diameter (which correlates with RV development), and whether coronary sinusoidal communications exist.

Cardiac catheterization is reserved for preoperative planning. In PA/IVS, catheterization is essential to determine whether the coronary circulation is RV-dependent, because this finding changes the entire surgical strategy. In PA/VSD, catheterization maps the MAPCA anatomy to guide unifocalization procedures. This is a high-yield testing point: the question stem may ask what additional study is needed before surgical intervention.

04Management and Treatment

The single most important management concept for the exam is this: PGE1 is the bridge to survival. The moment you suspect a duct-dependent cardiac lesion in a cyanotic neonate, start prostaglandin infusion. Do not wait for echocardiographic confirmation. The key side effect of PGE1 is apnea, so the infant should be monitored in an ICU setting with intubation capability readily available.

The surgical decision tree hinges on two anatomic questions. First, is the RV large enough to support a biventricular circulation? The tricuspid valve z-score is the primary metric; a z-score greater than -2 to -2.5 generally supports biventricular repair. Second, is the coronary circulation RV-dependent? If sinusoidal connections supply a substantial portion of the coronary bed, decompressing the RV would drop RV pressure and cause myocardial infarction. This is a classic exam trap: the test may describe a PA/IVS patient with coronary sinusoids and ask about the next step, where the wrong answer would be RV outflow tract surgery.

For PA/VSD, the concept of unifocalization is testable. MAPCAs arise from the aorta and supply lung segments in a disorganized fashion. The surgeon must connect these collaterals into a unified pulmonary arterial tree before definitive repair can be performed.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students lose points on pulmonary atresia questions is by failing to initiate PGE1 immediately. The vignette will describe a cyanotic newborn who does not improve with oxygen, and students may select "obtain echocardiography" or "obtain CXR" as the next best step. While those are correct diagnostically, the next best step in management is PGE1 infusion. Never delay prostaglandin for confirmatory imaging when duct-dependent physiology is suspected.

A second trap involves the distinction between PA/IVS and PA/VSD. The vignette may describe coronary sinusoidal communications and ask about surgical planning. Students who do not understand RV-dependent coronary circulation will incorrectly choose RV decompression, which would cause fatal myocardial ischemia. The correct pathway for these patients is single-ventricle palliation or transplant listing.

A third testing point is differentiating pulmonary atresia from critical pulmonary stenosis. Both are duct-dependent and cyanotic, but critical PS retains a harsh systolic ejection murmur and some antegrade flow on echo, while pulmonary atresia has no murmur from the RVOT and no forward flow. This distinction matters because critical PS may be treated with catheter-based balloon valvuloplasty alone, whereas pulmonary atresia requires a more complex surgical approach.

The core competency being tested is the ability to recognize duct-dependent cyanotic heart disease, initiate prostaglandin without delay, and understand how anatomy (RV size, coronary dependence, MAPCA distribution) dictates the surgical strategy.